Adipex-P Related Published Studies
Well-designed clinical trials related to Adipex-P (Phentermine)
Comparison of potency of ephedrine and mephentermine for prevention of post-spinal hypotension in caesarean section. [2008.05]
Randomised trial of intravenous infusion of ephedrine or mephentermine for management of hypotension during spinal anaesthesia for Caesarean section. [2005.01]
Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation. [2003.08]
A comparison of tyrosine against placebo, phentermine, caffeine, and D-amphetamine during sleep deprivation. [2003.08]
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. [2000.04.01]
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. [1999.12]
Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. [1996.04]
Steady-state pharmacokinetics of phentermine extended-release capsules. [1993.08]
Well-designed clinical trials possibly related to Adipex-P (Phentermine)
How physician obesity specialists use drugs to treat obesity. [2009.09]
Abuse liability assessment of atomoxetine in a drug-abusing population. [2008.05.01]
Combination of low doses of intrathecal ketamine and midazolam with bupivacaine improves postoperative analgesia in orthopaedic surgery. [2008.04]
Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. [2002.09]
Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. [2000.04]
Pharmacologic induction of weight loss to treat type 2 diabetes. [1999.06]
An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. [1998.09.10]
Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. [1997.05]
Other research related to Adipex-P (Phentermine)
Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. [2009.10]
Potency of mephentermine for prevention of post-spinal hypotension. [2009.07]
Oxethazaine as the source of mephentermine and phentermine in athlete's urine. [2009.03.10]
Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. [2008.08]
The longitudinal effects of fenfluramine-phentermine use. [2007.06]
Effects on weight reduction and safety of short-term phentermine administration in korean obese people. [2006.10.31]
Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. [2006.04]
Cusp tear in bicuspid aortic valve possibly caused by phentermine. [2006.01.13]
Phentermine and anaesthesia. [2005.08]
Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats. [2005.04.25]
Effects of phentermine and phenformin on biomarkers of aging in rats. [2005.01]
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. [2003.07.05]
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. [2002.03]
Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. [2002.02]
Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. [2002.01]
Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. [2001.12]
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. [2001.10.24]
A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule. [2001.03.01]
Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. [2000.11]
Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. [2000.05.02]
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. [2000.04.05]
Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats. [2000.01]
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. [1999.12.01]
Effects of phentermine on responding maintained by progressive-ratio schedules of cocaine and food delivery in rhesus monkeys. [1999.12]
Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. [1999.10]
Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota. [1999.08.01]
Synergistic interactions between fenfluramine and phentermine. [1999.07]
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. [1999.07]
Sympathetic overactivity from fenfluramine-phentermine overdose. [1999.06]
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. [1999.06]
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. [1999.05]
Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. [1999.05]
Effects of prenatal co-administration of phentermine and dexfenfluramine in rats. [1999.03.26]
Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine. [1998.10]
Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. [1998.05.30]
Effects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study. [1998.04]
Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects. [1998.04]
Schizophreniform-like psychotic disorder induced by phentermine: a case report. [1998.01]
Valvular heart disease associated with fenfluramine-phentermine. [1997.08.28]
Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. [1997.06]
Combined phentermine/fenfluramine administration enhances depletion of serotonin from central terminal fields. [1997.05]
Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. [1997.04.14]
Exposure to crystalline silica or treatment with chlorphentermine increases vitamin E levels in rat alveolar lavage materials. [1996.12.06]
Phentermine+fenfluramine produce cocaine-like discriminative cues. [1996]
Metabolism of phentermine and its derivatives in the male Wistar rat. [1993.06]
Possible association of ischemic stroke with phentermine. [1993.02]
Role of phospholipase C in chlorphentermine-induced pulmonary phospholipidosis in rat. [1988.05]
Other possibly related research studies
Finding new tricks for old drugs: an efficient route for public-sector drug discovery. [2005.12]
Pharmacotherapy for obesity. [2005]
Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. [2005.03.21]
Primary pulmonary arterial hypertension presenting as diffuse micronodules on CT. [2004]
Effects of anorectic drugs on food intake under progressive-ratio and free-access conditions in rats. [2004.11]
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. [2004.12]
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. [2004.12]
The long-term management of obesity with continuing pharmacotherapy. [2004.11]
Ischemic colitis after weight-loss medication. [2003.12]
Anorexigen-induced cardiac valvulopathy and female gender. [2003.04]
Medical monitoring for pharmaceutical injuries: tort law for the public's health? [2003.02.19]
Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. [2002.12]
Pharmacological management of obesity. [2002.12]
Anorexigen-related cardiopulmonary toxicity. [2000.09]
Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? [2002.09]
Appetite suppressants and valvular heart disease. [2002.09]
Diet medications and valvular heart disease: the current evidence. [2002.05]
Appetite suppressants and valvular heart disease - a systematic review. [2002.08.23]
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. [2002.06.15]
Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography. [2002.06]
Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. [2002.03]
Herbal therapy for management of obesity: observations from a clinical endocrinology practice. [2001.11]
Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. [2001.09]
Operation for anorexigen-associated valvular heart disease. [2001.10]
The relationship between health-related quality of life and weight loss. [2001.09]
Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. [2001.08.13]
Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. [2001.07]
Diet drugs and cardiac valvulopathy: a survey of dental patients. [2000.12]
Appetite suppressants and valvular heart disease. [2001.04]
Appetite-suppressing drugs and valvular heart disease. [1999.11]
[Obesity: principles of drug therapy] [2000.08]
[The obesity epidemics--do diet pills have a place in the treatment?] [2000.06.30]
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants] [1998.12.01]
The effects of drugs used to treat obesity on the autonomic nervous system. [2000.05]
Appetite suppressants and cardiac valvulopathy. Current clinical perspectives. [1999.10]
Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. [2000.05]
The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection. [1999]
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. [2000.03]
|
